Our findings suggest that IL-38 may have clinical potential not only as a promising prognostic predictor to identify individuals with poor prognostic potential, but also as a novel therapeutic target in the treatment of NSCLC. This evidence concerns the gene IL1F10 and non-small cell lung carcinoma.